The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Oceania Healthcare’s (OCA) Chief Executive, Earl Gasparich, has resigned from his role with the company
  • Earl held the position for seven years, during which time he oversaw the company’s listing on the ASX
  • Gasparich will succeed Glen Sowry as CEO of Metlifecare, following an announcement from the company today   
  • The Oceania Board has appointed Chief Financial Officer Brent Pattison as Acting Chief Executive Officer, effective immediately
  • Oceania is down 2.26 per cent, trading at $1.30

Oceania Healthcare’s (OCA) Chief Executive, Earl Gasparich, has resigned from his role with the company.

Oceania Healthcare is a leading provider of healthcare services in New Zealand.

The outgoing CEO first joined Oceania in August 2014 and led the company through a period of growth and transformation, including its initial public offering in May 2017 and the challenges of COVID-19.

Outside of his work at Oceania Healthcare, Gasparich also volunteers on the Boards of a number of charities involved in the provision of community services.

The Oceania Board has appointed Brent Pattison, Oceania Healthcare Chief Financial Officer, to the role of Acting Chief Executive Officer, effective immediately.

“The Board extend our gratitude and thanks to Earl for his contribution over his six and a half years with us,” said Oceania Chair Liz Coutts.

The company says they are now well positioned for growth in the years ahead.

Earl Gasparich will go on to succeed Glen Sowry as CEO of New Zealand-based retirement village provider Metlifecare.

“Earl knows the sector well and we are highly confident that he brings the skill and experience needed to deliver the ongoing leadership and capability to progress Metlifecare’s growth strategy,” said Metlifecare Chair, Paul McClintock.

Sowry will leave Metlifecare on March 31, and Gasparich is expected to commence at Metlifecare in the middle of the year.

Oceania is down 2.26 per cent, trading at $1.30 at 4:00 pm AEDT.

OCA by the numbers
More From The Market Online
Image of a woman holding a bottle of hemp oil

Little Green Pharma jumps into distribution with acquisition

Little Green Pharma is aiming to make the strategic acquisition of HH (Australia) Pty Ltd to…
Image of cancer cells

Radiopharm approved to start Lu-RAD202 safety trials, door open for in-human studies

Radiopharm Theranostics has received ethics approval for its trial into Lu-RAD202, a novel treatment for these…
Close up of a nasal spray

LTR Pharma pairs with Men’s Health Downunder for supply of erectile dysfunction spray

LTR Pharma Ltd has signed an agreement with Men's Health Downunder to facilitate supply of its…
Immune system concept ai gen

Immutep dips as safety test for flagship drug IMP761 shows no adverse effects

Immutep has reported a small-scale conceptual safety test among 5 patients using flagship drug IMP761 has…